Biopharmaceutical CMO amp CRO

Biopharmaceutical CMO & CRO Market Outlook

The global biopharmaceutical Contract Manufacturing Organization (CMO) and Contract Research Organization (CRO) market is projected to reach approximately USD 290 billion by 2035, growing at a compound annual growth rate (CAGR) of around 8.3% during the forecast period from 2025 to 2035. The increasing demand for biopharmaceuticals, driven by the rise in chronic diseases and the aging population, is a significant growth factor contributing to this expansion. Additionally, the increased outsourcing of research and manufacturing capabilities by pharmaceutical companies to optimize costs and speed up time-to-market is enhancing the market dynamics. The advancements in biotechnological processes, coupled with the growing complexity of drug development and regulatory requirements, are pushing firms to collaborate with specialized CMOs and CROs, offering comprehensive solutions to navigate these challenges. Furthermore, the ongoing COVID-19 pandemic has surged demand for effective vaccines and therapeutics, further catalyzing growth in the CMO and CRO sectors.

Growth Factor of the Market

The biopharmaceutical CMO and CRO market is primarily driven by the increasing trend of outsourcing by pharmaceutical companies. As firms strive to cut costs, reduce timeframes for drug development, and mitigate risks associated with in-house production, the reliance on CMOs and CROs has intensified. This outsourcing trend allows companies to leverage external expertise and technologies, focusing their resources on core activities while ensuring high-quality manufacturing and research services. Additionally, the rapid advancements in biopharmaceutical technologies, such as gene and cell therapies, necessitate specialized manufacturing techniques, further boosting the demand for CMOs. The rise in the prevalence of chronic diseases, along with the demand for personalized medicines, is propelling research activities, thus benefiting the CRO sector. Regulatory complexities also require specialized knowledge, creating opportunities for CROs to expand their service offerings, thereby fueling market growth.

Key Highlights of the Market

• Significant growth in demand for biopharmaceuticals, particularly in oncology and infectious diseases.
• Increase in outsourcing trends among pharmaceutical companies, driven by cost efficiencies.
• Technological advancements facilitating improved efficiency in drug development and manufacturing.
• Regulatory complexities creating opportunities for specialized CRO services.
• Growing prevalence of chronic diseases leading to heightened research and development activities.

By Service Type

Manufacturing Services:

The manufacturing services segment is a crucial component of the biopharmaceutical CMO market, providing essential capabilities for producing biopharmaceutical products at scale. This segment encompasses a wide range of services, including process development, scale-up, and commercial manufacturing. As biopharmaceutical products often require complex manufacturing processes, CMOs specializing in this area are increasingly sought after by pharmaceutical companies. The need for flexibility in manufacturing facilities, capable of accommodating various scales and production methods, is driving demand for sophisticated manufacturing services. Additionally, the increasing focus on biologics and biosimilars is further propelling this segment's growth, as companies seek to leverage external expertise to meet market demands while ensuring compliance with regulatory standards.

Drug Development Services:

The drug development services segment plays a pivotal role in the CRO market, encompassing a range of activities from preclinical research to post-marketing surveillance. This segment is growing rapidly as companies aim to streamline the drug development process and reduce time-to-market. CROs provide essential services such as formulation development, stability testing, and toxicology studies, which are critical in determining a drug's safety and efficacy. The increasing complexity of drug formulations, particularly in biologics and advanced therapies, necessitates specialized expertise, leading many pharmaceutical companies to partner with CROs. Furthermore, the rising costs associated with drug development are prompting companies to seek efficient and cost-effective solutions, thereby enhancing the demand for comprehensive drug development services.

Clinical Research Services:

Clinical research services are integral to the CRO landscape, focusing on managing clinical trials that evaluate the safety and efficacy of new drugs. This segment has witnessed significant growth due to the increasing number of clinical trials being conducted globally, driven by the need for innovative treatments and therapies. CROs offer a multitude of services within this domain, including trial design, patient recruitment, data management, and regulatory compliance. As pharmaceutical companies look to optimize their clinical trial processes, the demand for experienced CROs capable of navigating regulatory environments and managing complex trial protocols has surged. Additionally, the ongoing evolution of trial methodologies, such as decentralized and adaptive trials, is reshaping how clinical research services are delivered, further boosting this segment's growth.

Laboratory Services:

Laboratory services represent a vital segment within the CMO and CRO markets, providing critical support for research, development, and manufacturing processes. This segment includes a range of analytical services, bioanalytical testing, and quality control testing essential for ensuring the safety and efficacy of biopharmaceutical products. The growing emphasis on quality assurance and regulatory compliance is driving demand for laboratory services as companies must ensure that their products meet stringent quality standards. Furthermore, advancements in analytical technologies, such as high-throughput screening and mass spectrometry, are enabling laboratories to enhance their testing capabilities, providing faster and more accurate results. As the biopharmaceutical industry continues to expand, the reliance on specialized laboratory services will only increase.

Regulatory Services:

Regulatory services are an essential component of the CRO market, assisting biopharmaceutical companies in navigating the complex regulatory landscape associated with drug development and approval processes. This segment has become increasingly important as regulatory requirements become more stringent globally. CROs that offer regulatory services provide guidance on compliance with local and international regulations, submission of documentation, and interaction with regulatory agencies. The growing need for expedited drug approvals, especially for critical therapies such as those targeting rare diseases or public health crises, is heightening the demand for experienced regulatory consultants. The ability to effectively manage regulatory submissions and ensure compliance can significantly impact a company's success in bringing their products to market.

By Therapeutic Area

Oncology:

The oncology therapeutic area is one of the most significant segments within the biopharmaceutical CMO and CRO market, driven by the increasing prevalence of cancer worldwide. With the rising incidence of various cancers, there is a dire need for innovative therapies and treatment options, prompting pharmaceutical companies to invest heavily in research and development. CMOs and CROs specializing in oncology are thus in high demand as they offer tailored services that address the unique challenges of oncology drug development, including complex clinical trial designs and patient recruitment strategies. Furthermore, advancements in personalized medicine and targeted therapies are revolutionizing the oncology landscape, necessitating specialized knowledge and expertise from CMOs and CROs to navigate these complexities effectively.

Infectious Diseases:

The infectious diseases segment is experiencing notable growth within the biopharmaceutical CMO and CRO market, largely attributed to the ongoing global health challenges posed by emerging infectious diseases. The COVID-19 pandemic has underscored the need for rapid vaccine development and therapeutic interventions, driving increased investments in this therapeutic area. In response, many pharmaceutical companies are collaborating with CMOs and CROs to expedite the research and development of vaccines and treatments for infectious diseases. This collaboration focuses on leveraging external capabilities to conduct preclinical testing, clinical trials, and regulatory submissions more efficiently, enhancing the overall response to public health emergencies. The growing urgency for effective infectious disease therapies is expected to sustain demand in this sector.

Neurology:

The neurology therapeutic area is gaining prominence within the biopharmaceutical CMO and CRO market as the prevalence of neurological disorders continues to rise globally. Conditions such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis are becoming increasingly common, leading to heightened research efforts aimed at developing effective treatments. The complexities associated with neurological drug development necessitate specialized expertise in understanding the intricacies of the central nervous system, and many pharmaceutical companies are turning to CMOs and CROs for support. These organizations offer critical services related to preclinical research, clinical trial design, and patient recruitment, which are essential for advancing breakthroughs in neurology. As research in this field continues to evolve, the demand for specialized services will grow accordingly.

Cardiovascular Diseases:

Cardiovascular diseases remain a leading cause of morbidity and mortality globally, driving significant investment in research and development within the biopharmaceutical CMO and CRO market. The urgency to develop new therapies and interventions for heart diseases has led pharmaceutical companies to collaborate with CMOs and CROs that possess expertise in clinical trial management and regulatory compliance specific to cardiovascular research. This collaboration is crucial for navigating the challenges associated with conducting large-scale clinical trials and ensuring efficacy and safety standards are met. As cardiovascular research continues to be a priority for public health, the demand for specialized CMOs and CROs in this therapeutic area is expected to rise significantly, further enhancing market growth.

Respiratory Diseases:

The respiratory diseases therapeutic area is an important segment within the biopharmaceutical CMO and CRO market, driven by the increasing prevalence of chronic respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). The demand for new therapeutic options and innovative delivery methods is pushing pharmaceutical companies to enhance their research efforts in this area. CMOs and CROs specializing in respiratory diseases provide essential support in terms of preclinical testing, clinical trial execution, and regulatory submissions tailored to respiratory therapeutics. The growing understanding of the pathophysiology of respiratory diseases and advancements in inhalation technologies are also driving innovations, necessitating the expertise of specialized organizations to navigate these evolving demands effectively.

By User

Pharmaceutical & Biotechnology Companies:

Pharmaceutical and biotechnology companies are the primary users of CMO and CRO services, leveraging these partnerships to enhance their research and production capabilities. These companies often face increasing pressures to innovate and bring new drugs to market swiftly, which necessitates the use of external services for manufacturing and clinical research. CMOs and CROs provide critical advantages in terms of cost-effectiveness, flexibility, and specialized expertise, allowing pharmaceutical and biotechnology firms to focus on their core competencies while relying on established service providers for high-quality results. With the rise of personalized medicine and biotechnology advancements, the collaboration between these companies and CMOs/CROs is expected to deepen, driving further growth in the market.

Medical Device Companies:

Medical device companies represent a growing user segment within the biopharmaceutical CMO and CRO market, particularly as the lines between pharmaceuticals and medical devices continue to blur with the advent of combination products. These companies are increasingly seeking specialized manufacturing and research services to support the development of innovative devices that often require rigorous testing and regulatory compliance. CMOs and CROs offer valuable expertise in managing clinical trials, conducting testing, and ensuring compliance with regulatory standards, all of which are essential for successful product launches. As the demand for advanced medical devices rises, especially those addressing chronic diseases and conditions, the reliance on CMO and CRO services is anticipated to expand significantly in this sector.

Academic & Research Institutes:

Academic and research institutes are increasingly utilizing CMO and CRO services to enhance their research capabilities and expedite the translation of discoveries into clinical applications. These institutions often collaborate with CMOs and CROs to facilitate drug development, clinical trials, and regulatory submissions, leveraging external expertise to navigate the complexities of bringing new therapies to market. The partnership allows academic researchers to focus on their core research while ensuring that their findings can be effectively developed and tested in real-world settings. As research institutes continue to engage in translational medicine and innovative therapeutic approaches, the demand for specialized CMO and CRO services from this user segment is expected to increase.

Contract Research Organizations:

Contract Research Organizations (CROs) themselves also engage in partnerships with other CROs and CMOs to optimize their service offerings and enhance capabilities. This collaboration allows them to expand their portfolio of services, including advanced data management, patient recruitment strategies, and specialized laboratory testing. As CROs seek to provide comprehensive solutions to their clients, the demand for specialized CMO services becomes a crucial aspect of their operations. This symbiotic relationship often leads to enhanced service quality, efficiency, and innovation in drug development and manufacturing processes, ultimately benefiting the broader biopharmaceutical ecosystem. The continuous evolution of CRO services will likely drive further collaboration with CMOs, fueling growth in the overall market.

By Region

The North American region holds a significant portion of the biopharmaceutical CMO and CRO market, accounting for nearly 45% of the global market share. This dominance can be attributed to advanced healthcare infrastructure, a strong presence of major pharmaceutical and biotechnology companies, and substantial investments in research and development. Furthermore, the regulatory environment in North America facilitates innovation, allowing for faster drug approvals, which has made it an attractive region for CMO and CRO operations. The growth in the oncology and infectious disease segments is particularly notable in this region, driven by increasing research initiatives and the urgent need for new therapeutics. The market in North America is expected to grow at a CAGR of around 8.1% during the forecast period, reflecting continued investment and innovation.

In Europe, the biopharmaceutical CMO and CRO market is also witnessing significant growth, accounting for approximately 30% of the global market share. The region is characterized by a robust pharmaceutical industry that emphasizes collaboration between academic institutions, research organizations, and industry players. The ongoing efforts to address chronic diseases and the increasing focus on personalized medicine are driving demand for specialized services. Countries such as Germany, France, and the UK are leading the way in terms of research investments, further enhancing the growth opportunities for CMOs and CROs. The European market is anticipated to grow at a CAGR of around 7.8%, supported by favorable regulatory conditions and a growing emphasis on innovative therapies in various therapeutic areas.

Opportunities

The biopharmaceutical CMO and CRO market presents numerous opportunities for growth, particularly as pharmaceutical companies continue to embrace outsourcing as a strategic approach to enhance efficiency and reduce operational risk. One of the most significant opportunities lies in the increasing focus on personalized medicine and biologics, which necessitates specialized manufacturing processes and expert knowledge. As biopharmaceutical companies pivot towards these innovative therapies, the demand for specialized CMO and CRO services will rise, creating a significant market expansion opportunity. Furthermore, the ongoing advancements in technology, such as artificial intelligence and machine learning, are transforming research and manufacturing processes, enhancing productivity, and improving decision-making. Companies that leverage these technologies can position themselves favorably in a highly competitive landscape, capturing a larger share of the market.

Additionally, the growing emphasis on patient-centric drug development offers fertile ground for CMOs and CROs to provide tailored solutions that cater to the unique needs of patients. The shift towards patient engagement and the incorporation of real-world evidence into clinical trials are becoming increasingly important in the drug development process. By offering services that prioritize patient perspectives and experiences, CMOs and CROs can differentiate themselves in the market and attract more clients. Moreover, the rising global health challenges, such as pandemics and the increasing prevalence of chronic diseases, underscore the urgent need for innovative therapies, thereby creating ample opportunities for CMOs and CROs to contribute meaningfully to global health initiatives while simultaneously driving their growth.

Threats

While the biopharmaceutical CMO and CRO market offers considerable opportunities, it is not without its challenges. One of the primary threats is the increasing competition among service providers, which can lead to price wars and margin erosion. As more companies enter the CMO and CRO space, established players may be pressured to reduce costs to maintain market share, potentially compromising quality and service standards. Additionally, the reliance on third-party providers for critical services raises concerns regarding data security and confidentiality, particularly in an era where data breaches are increasingly common. Companies must invest in robust data protection measures to mitigate these risks and maintain client trust, which can incur additional costs and operational complexities. Moreover, fluctuating regulatory environments across different regions can pose significant challenges for CMOs and CROs, as compliance with varying regulations can be resource-intensive and may hinder operational efficiency.

Another concern for the biopharmaceutical CMO and CRO market is the evolving landscape of technology and methodologies in drug development. As advancements in technologies such as gene editing and artificial intelligence gain momentum, traditional approaches to drug development may become obsolete. Companies that fail to adapt to these technological changes risk falling behind their competitors, losing market relevance. This threat necessitates ongoing investment in research and development, employee training, and the adoption of new technologies to remain competitive. Furthermore, the potential impact of global economic fluctuations on healthcare budgets and research funding could lead to reduced investments in biopharmaceutical development, thus posing a threat to the growth of CMOs and CROs.

Competitor Outlook

• Covance Inc.
• Charles River Laboratories International, Inc.
• PPD, Inc.
• Syneos Health
• ICON plc
• Laboratory Corporation of America Holdings
• Forte Research Systems, Inc.
• WuXi AppTec
• Samsung Biologics
• Lonza Group AG
• Recipharm AB
• Medpace Holdings, Inc.
• Eurofins Scientific SE
• Thermo Fisher Scientific Inc.
• PRA Health Sciences, Inc.

The competitive landscape of the biopharmaceutical CMO and CRO market is characterized by a diverse array of players, ranging from large multinational corporations to specialized niche firms. Major companies such as Covance Inc., Charles River Laboratories, and ICON plc dominate the market, offering comprehensive services that span the drug development lifecycle. These companies leverage their extensive experience and established reputations to attract clients, often providing integrated solutions that encompass a wide range of services from preclinical research to regulatory submission. As competition intensifies, many firms are strategically investing in technological advancements and expanding their service offerings to differentiate themselves and capture greater market share. The emphasis on quality, compliance, and efficiency is driving these organizations to innovate continuously, enhancing their capabilities to better serve their clients.

Companies like Lonza Group AG and Samsung Biologics are noteworthy players in the manufacturing segment of the CMO market, specializing in biologics and biosimilars. Their capabilities in large-scale production and expertise in complex manufacturing processes position them as leaders in the industry. These companies are continuously exploring opportunities for expansion, whether through strategic partnerships, acquisitions, or investments in new technologies. Their focus on manufacturing excellence and adherence to stringent quality standards ensures that they remain competitive in a rapidly evolving market. As demand for biologics continues to surge, these firms are well-positioned to capitalize on growth opportunities while delivering value to their clients.

Another significant player, PPD, Inc., has established a robust presence in the CRO market, offering a comprehensive suite of services designed to meet the needs of pharmaceutical and biotechnology clients. Their expertise in clinical trials, regulatory compliance, and data management has enabled them to build strong relationships with clients across various therapeutic areas. By continuously investing in cutting-edge technologies and enhancing their service offerings, PPD, Inc. aims to maintain its competitive edge in the market. The company's commitment to innovation, coupled with its extensive experience in managing complex clinical development programs, positions it favorably in the competitive landscape. As pharmaceutical companies increasingly seek strategic partnerships with reliable CROs, PPD, Inc. is well-positioned to capture a larger share of the growing market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 ICON plc
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 PPD, Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 WuXi AppTec
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Covance Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Recipharm AB
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Syneos Health
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Lonza Group AG
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Samsung Biologics
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Eurofins Scientific SE
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Medpace Holdings, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 PRA Health Sciences, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Forte Research Systems, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Thermo Fisher Scientific Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Laboratory Corporation of America Holdings
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Charles River Laboratories International, Inc.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Biopharmaceutical CMO amp CRO Market, By User
    • 6.1.1 Pharmaceutical & Biotechnology Companies
    • 6.1.2 Medical Device Companies
    • 6.1.3 Academic & Research Institutes
    • 6.1.4 Contract Research Organizations
  • 6.2 Biopharmaceutical CMO amp CRO Market, By Service Type
    • 6.2.1 Manufacturing Services
    • 6.2.2 Drug Development Services
    • 6.2.3 Clinical Research Services
    • 6.2.4 Laboratory Services
    • 6.2.5 Regulatory Services
  • 6.3 Biopharmaceutical CMO amp CRO Market, By Therapeutic Area
    • 6.3.1 Oncology
    • 6.3.2 Infectious Diseases
    • 6.3.3 Neurology
    • 6.3.4 Cardiovascular Diseases
    • 6.3.5 Respiratory Diseases

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Biopharmaceutical CMO amp CRO Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Biopharmaceutical CMO amp CRO market is categorized based on

By Service Type

• Manufacturing Services
• Drug Development Services
• Clinical Research Services
• Laboratory Services
• Regulatory Services

By Therapeutic Area

• Oncology
• Infectious Diseases
• Neurology
• Cardiovascular Diseases
• Respiratory Diseases

By User

• Pharmaceutical & Biotechnology Companies
• Medical Device Companies
• Academic & Research Institutes
• Contract Research Organizations

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Covance Inc.
• Charles River Laboratories International, Inc.
• PPD, Inc.
• Syneos Health
• ICON plc
• Laboratory Corporation of America Holdings
• Forte Research Systems, Inc.
• WuXi AppTec
• Samsung Biologics
• Lonza Group AG
• Recipharm AB
• Medpace Holdings, Inc.
• Eurofins Scientific SE
• Thermo Fisher Scientific Inc.
• PRA Health Sciences, Inc.